14-Aminocamptothecins: Their Synthesis, Preclinical Activity, and Potential Use for Cancer Treatment

Mark Matteucci(Threshold Pharmaceuticals (United States)), Fanying Meng(Shanghai University), Jackson Matteucci(Threshold Pharmaceuticals (United States)), Charles P. Hart(University of Auckland), Brian Jung(Threshold Pharmaceuticals (United States)), Heli Huang(Threshold Pharmaceuticals (United States)), Deepthi Bhupathi(University of Auckland), Qian Liu(Southeast University), Hailong Jiao(Threshold Pharmaceuticals (United States)), Jessica D. Sun(Threshold Pharmaceuticals (United States)), Dharmendra Ahluwalia(Threshold Pharmaceuticals (United States)), Xiaohong Cai(Wenzhou Medical University), Donald Jung(Anshan Hospital)
Journal of Medicinal Chemistry
February 22, 2011
10.1021/jm101354u
Cited by 21

Related Papers

Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma
|Cell|2019|1.2k
Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
|Molecular Cancer Therapeutics|2011|206
DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis
|Journal of Hematology & Oncology|2018|125
OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL
|Clinical Cancer Research|2019|53
Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer
|Cancer Biology & Therapy|2015|51